Moberg Pharma Nails Antifungal Drug Agreement with Bayer, an Industrial Info Market Brief
Attachment: Bayer
Moberg Pharma has entered into an exclusive agreement with Bayer for the marketing, distribution and sales of its MOB-015 drug, which is used in the topical treatment of onychomycosis, a fungal infection of the nail. This gives Bayer exclusive European rights to MOB-015 upon completion of Phase II clinical development and registration.
Bayer has 15 operational sites in Europe. See map below.
